Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell...

Area of Science:

• Immunology
• Molecular Biology
• Vaccine Development

Background:

• Heparan sulfates (HS) are components of ubiquitously expressed HS proteoglycans (HSPGs).
• HSPGs act as attachment points for various molecules and influence numerous biological processes.
• Previous work indicated HSPGs enhance MHC class II-restricted antigen presentation.

Purpose of the Study:

• To investigate if HSPG targeting influences other aspects of immune responses beyond MHC class II presentation.
• To determine the impact of HSPG-targeted antigens on both CD4(+) and CD8(+) T-cell responses.
• To evaluate the efficacy of HSPG and MHC-II co-targeted antigens in controlling tumor growth.

Main Methods:

• Coupling of HS ligands to antigens to assess their effect on antigen presentation.
• Evaluating T-cell stimulation capacity in vitro and CD8(+) immune responses in vivo in mice.
• Immunizing animals with tumor-antigen constructs targeting HSPGs and MHC-II to assess tumor control.

Main Results:

• Antigen presentation to both CD4(+) and CD8(+) T-cells is increased when antigens are coupled to HS ligands.
• This enhanced antigen presentation correlates with a stronger CD8(+) immune response in mice.
• Animals immunized with HSPG and MHC-II co-targeted antigens demonstrated improved control of tumor cell growth.

Conclusions:

• Ubiquitous molecules like HSPGs can modulate both MHC class I- and MHC class II-restricted antigen presentation.
• HSPGs function as co-receptors in T-cell stimulation, enhancing immune responses.
• Tumor-antigens designed to target both HSPGs and MHC-II hold promise for developing potent vaccines against tumors.